BrightPath Biotherapeutics Co., Ltd

Looking for a EU partner for licensing agreement

KEY ACTIVITIES Drug and drug discovery
SECTOR: Pharmaceutical
KEY WORDS: Cancer cell, Immuno-modulatory antibody
TYPE OF ACTIVITIES R&D cooperation

Company Activity Description:

BrightPath Biotherapeutics is a Japan-based clinical-stage biopharmaceutical company focused on research and development of novel cancer immunotherapeutics. The company pipeline includes cancer peptide vaccine, rejuvenated T-cell therapy, and immuno-modulator antibodies.

 

BrightPath Biotherapeutics is also conducting research and development regarding cancer neoantigen.

 

Type of Partnership Sought:

1.License agreement

 

Additional information:

BrightPath Biotherapeutics is aiming to license its latest researches.

# Out-license of GRN-1201 and GRN-1301

# In-license/collaboration of research or early-stage clinical programs and related technologies regarding;

   - Cancer cell therapy

   - Immuno-modulatory antibody

   - Cancer neoantigen

Products & Service Stage Outline
1) GRN-1201 Phase 2 in combination with immuno-checkpoint inhibitor  (Indication: NSCLC) A cancer peptide vaccine comprising four peptide antigens
2) GRN-1301 Basic research (Indication: NSCLC) A cancer neoantigen peptide vaccine targeting non-small cell lung cancer with EGFR-T790M point mutation
3) iPS-T cell therapy Basic research (Indication: Lymphoma) Induced pluripotent stem cell (iPSC)-derived, rejuvenated T cell therapy

 

Link to Full detail of the presentation

Company website